Fed. Circ. Impeding Biopharma Innovation, Justices Told
Bristol-Myers Squibb Co. and three other drug companies have urged the U.S. Supreme Court to take up a case challenging the Federal Circuit's decision to impose different standards on the written...To view the full article, register now.
Already a subscriber? Click here to view full article